We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

214 hedge funds and large institutions have $376M invested in Nektar Therapeutics in 2022 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 68 increasing their positions, 73 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more call options, than puts

Call options by funds: $48K | Put options by funds: $33K

0.25% less ownership

Funds ownership: 6.24% → 5.99% (-0.25%)

7% less repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 73

7% less funds holding

Funds holding: 230 → 214 (-16)

33% less capital invested

Capital invested by funds: $561M → $376M (-$185M)

34% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 38

Holders
214
Holders Change
-16
Holders Change %
-6.96%
% of All Funds
3.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
68
Reduced
73
Closed
38
Calls
$48K
Puts
$33K
Net Calls
+$15K
Net Calls Change
-$1.77M

Top Buyers

1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$4.95M
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$4.19M
3
Federated Hermes
Federated Hermes
Pennsylvania
+$3.28M
4
ABG
Ally Bridge Group
New York
+$2.91M
5
BlackRock
BlackRock
New York
+$2.84M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$36.4M
2
AllianceBernstein
AllianceBernstein
Tennessee
-$2.47M
3
Primecap Management
Primecap Management
California
-$2.46M
4
Morgan Stanley
Morgan Stanley
New York
-$2.13M
5
State Street
State Street
Massachusetts
-$1.68M
Name Holding Trade Value Shares
Change 		Change in
Stake
Balyasny Asset Management
226
Balyasny Asset Management
Illinois
– -$46K -967 Closed
CC
227
Cipher Capital
New York
– -$46K -967 Closed
Mariner
228
Mariner
Kansas
– -$45K -932 Closed
Verition Fund Management
229
Verition Fund Management
Connecticut
– -$38K -783 Closed
Aberdeen Group
230
Aberdeen Group
United Kingdom
– -$36K -750 Closed
AWA
231
Arete Wealth Advisors
Illinois
– -$35K -733 Closed
STAS
232
Strong Tower Advisory Services
Minnesota
– -$34K -710 Closed
RJA
233
Raymond James & Associates
Florida
– -$32K -667 Closed
PHK
234
Point72 Hong Kong
Hong Kong
– -$10K -201 Closed
DFCM
235
Dark Forest Capital Management
Puerto Rico
– -$9K -188 Closed
QCG
236
Quadrant Capital Group
Ohio
– -$1K -27 Closed
AAP
237
Arax Advisory Partners
Colorado
– -$1K -18 Closed
SWA
238
Sutton Wealth Advisors
Florida
– -$602 -13 Closed
BTI
239
Blue Trust Inc
Georgia
– -$581 -12 -67%
BCWM
240
Bartlett & Co Wealth Management
Ohio
– -$320 -7 Closed
MG
241
MilWealth Group
Wisconsin
– -$317 -7 Closed
6 7 8 9
10

NKTR Hedge Fund Activity: Q4 2022 in Review

214 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q4 2022, worth a combined $376M — down 33% from $561M a quarter earlier.

Sellers outnumbered buyers: 38 funds closed out of NKTR and 25 opened new positions — a net loss of 13 holders — while 73 trimmed existing stakes and 68 added.

The largest buyer was Jacobs Levy Equity Management, adding an estimated $4.95M. The largest seller was Wellington Management Group, exiting entirely with an estimated $36.4M sold.

  • 214 institutional investors held Nektar Therapeutics (NKTR) as of Q4 2022, down from 230 in Q3 2022.
  • Funds reported $376M of Nektar Therapeutics stock for Q4 2022, down 33% quarter-over-quarter.
  • 25 funds opened new Nektar Therapeutics positions in Q4 2022 and 38 closed out, a net change of -13 holders.
  • The largest Nektar Therapeutics buyer in Q4 2022 was Jacobs Levy Equity Management, an estimated $4.95M added.
  • The largest Nektar Therapeutics seller in Q4 2022 was Wellington Management Group, an estimated $36.4M sold.

Based on aggregated 13F filings for Q4 2022.